In last trading session, Heron Therapeutics Inc (NASDAQ:HRTX) saw 1.02 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $1.72 trading at $0.03 or 1.78% at ring of the bell on the day assigns it a market valuation of $261.60M. That closing price of HRTX’s stock is at a discount of -128.49% from its 52-week high price of $3.93 and is indicating a premium of 39.53% from its 52-week low price of $1.04.

For Heron Therapeutics Inc (HRTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.03 in the current quarter.

Heron Therapeutics Inc (NASDAQ:HRTX) trade information

Upright in the green during last session for gaining 1.78%, in the last five days HRTX remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.72 price level, adding 6.05% to its value on the day. Heron Therapeutics Inc’s shares saw a change of 12.42% in year-to-date performance and have moved 3.61% in past 5-day. Heron Therapeutics Inc (NASDAQ:HRTX) showed a performance of 5.52% in past 30-days.

Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 75.43% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 9. It follows that stock’s current price would drop -190.7% in reaching the projected high whereas dropping to the targeted low would mean a loss of -190.7% for stock’s current value.

Heron Therapeutics Inc (HRTX) estimates and forecasts

This year revenue growth is estimated to rise 10.88% from the last financial year’s standing.

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 37.37M for the same. And 1 analysts are in estimates of company making revenue of 34.25M in the next quarter. Company posted 34.23M and 34.67M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.01% during past 5 years.

Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders

RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at HRTX for having 26.71 million shares of worth $93.5 million. And as of 2024-06-30, it was holding 17.5395 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 8.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.6984 of outstanding shares, having a total worth of $30.16 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 4.68 shares of worth $8.06 million or 3.08% of the total outstanding shares. The later fund manager was in possession of 3.29 shares on Nov 30, 2024 , making its stake of worth around $5.67 million in the company or a holder of 2.17% of company’s stock.